Ieq Capital LLC Acquires Shares of 3,065 Prestige Consumer Healthcare Inc. (NYSE:PBH)

Ieq Capital LLC bought a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 3,065 shares of the company's stock, valued at approximately $239,000.

Several other large investors have also added to or reduced their stakes in PBH. New York State Common Retirement Fund lifted its stake in Prestige Consumer Healthcare by 5.1% during the 4th quarter. New York State Common Retirement Fund now owns 16,098 shares of the company's stock valued at $1,257,000 after acquiring an additional 778 shares in the last quarter. Kestra Investment Management LLC bought a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at about $27,000. Truist Financial Corp purchased a new position in Prestige Consumer Healthcare during the fourth quarter worth about $345,000. Sanctuary Advisors LLC grew its stake in Prestige Consumer Healthcare by 5.4% in the 4th quarter. Sanctuary Advisors LLC now owns 18,175 shares of the company's stock valued at $1,425,000 after purchasing an additional 927 shares during the period. Finally, Principal Financial Group Inc. raised its stake in shares of Prestige Consumer Healthcare by 3.2% in the fourth quarter. Principal Financial Group Inc. now owns 256,526 shares of the company's stock valued at $20,032,000 after buying an additional 7,890 shares during the period. Institutional investors own 99.95% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on PBH. Canaccord Genuity Group increased their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Sidoti downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 target price on the stock. in a research note on Monday, December 9th. Raymond James raised shares of Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. DA Davidson lifted their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Finally, StockNews.com upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $92.60.

Remove Ads

Prestige Consumer Healthcare Trading Up 0.1 %

NYSE PBH traded up $0.10 during trading on Tuesday, hitting $85.35. 204,442 shares of the company's stock traded hands, compared to its average volume of 314,364. The firm has a market cap of $4.23 billion, a P/E ratio of 19.98, a PEG ratio of 2.69 and a beta of 0.50. The stock has a fifty day moving average of $80.18 and a two-hundred day moving average of $77.40. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $88.36.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. As a group, sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.